REGARD: Demographic and baseline characteristics were similar between treatment arms¹,²

REGARD: DEMOGRAPHIC AND BASELINE CHARACTERISTICS2

REGARD demographic and baseline characteristics

ECOG=Eastern Cooperative Oncology Group; PS=performance status.

References:
  1. CYRAMZA (ramucirumab) [package insert]. India, Eli Lilly & Company (India) Pvt. Ltd.
  2. Fuchs CS, Tomasek J, Yong CJ, et al; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31-39.
Top